Abstracts tagged "Juvenile Inflammatory Arthritis"

Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Marianne Kerski¹, Smriti Mohan¹, Cynthia Vizcaya², Reema Sutariya³, Weibin Bao³ and Matthew Stoll⁴, ¹University of Michigan, Ann Arbor, MI, ²Novartis Pharmaceutical Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…
Abstract Number: 1309 • ACR Convergence 2024
Bridging the Gap: Evaluating Ophthalmology Training Amongst Pediatric Rheumatology Fellows
Jully Padam¹, Tzielan Lee² and Rajdeep Pooni³, and Childhood Arthritis and Rheumatology Research Alliance., ¹Stanford University, Redwood City, CA, ²Stanford University School of Medicine, Palo Alto, CA, ³Stanford University, Palo Alto, CA
Background/Purpose: The scarcity of literature surrounding ophthalmology training within non-ophthalmology specialties is striking. Chan et al. highlighted this gap revealing a discomfort among family medicine…
Abstract Number: 1771 • ACR Convergence 2024
Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics
Mireia Lopez Corbeto¹, yolanda Guillen², Irene Bonafonte³, Nuria Palau⁴, Raül Tortosa⁴, Estefanía Moreno Ruzafa¹, Antonio Julia⁵ and Sara Marsal⁶, ¹Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain, ²Imidomics, Inc, Barcelona, Spain, ³Berufserfahrung: Helmholtz Munich, Barcelona, Spain, ⁴Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, ⁵Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁶Vall Hebron Hospital Research Institute, Barcelona, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a prevalent rheumatic disease in children, comprising seven subtypes. The most common, oligoarticular JIA (oJIA), accounts for 30-60% of…
Abstract Number: 1915 • ACR Convergence 2024
Patient-reported Difficulties Regarding Reproductive Health Discussions in an Urban Outpatient Setting
Martha Delgado¹, Cassidy Hernandez-Tamayo², Melissa Wilson² and Leanna Wise³, ¹Los Angeles General Hospital/Keck Medicine of USC, Costa Mesa, CA, ²Keck School of Medicine of USC, Los Angeles, CA, ³LAGMC/Keck Medicine of USC, Los Angeles, CA
Background/Purpose: Timely reproductive health conversations in the rheumatology outpatient setting are essential for optimal maternal-fetal health; however, the literature suggests that these conversations happen for…
Abstract Number: 1945 • ACR Convergence 2024
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates
John Bridges¹, Eileen Rife², Randy Cron³, Livie Timmerman⁴, Linda McAllister⁵, Annelle Reed⁶, Carolyn Smith⁷, Emily Smitherman³, Matthew Stoll³, Bethany Walker⁵ and Melissa Mannion³, ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Gardendale, AL, ⁵Children's of Alabama, Trussville, AL, ⁶Children's of Alabama, Tuscaloosa, AL, ⁷Children's of Alabama, Birmingham, AL
Background/Purpose: The transition period from pediatric to adult-oriented rheumatology care is a high-risk time for disease flare and poor outcomes. We previously demonstrated implementation of…
Abstract Number: 0359 • ACR Convergence 2023
Clinical Characteristics of Patients with Juvenile Idiopathic Arthritis Who Undergo Adalimumab Drug Level Testing and Anti-Drug Antibody Assessment
Chelsea Vallejos¹, Jennifer Cooper² and Ingrid Pan¹, ¹Children's Hospital Colorado, Aurora, CO, ²University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Adalimumab therapeutic drug monitoring (TDM) using established trough concentrations is not standard practice in JIA patients, unlike IBD. No specific guidelines outline a therapeutic…
Abstract Number: 0364 • ACR Convergence 2023
Sex Differences in Clinical and Imaging Characteristics of Axial Juvenile Spondyloarthritis
Adam Mayer¹, Timothy G. Brandon², Pamela F. Weiss³ and on behalf of the JAXSPERT members², ¹University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The extent to which heterogeneity exists in youth with axial disease and juvenile spondyloarthritis (JSpA) is unclear. In a cross-sectional sample of patients classified…
Abstract Number: 0831 • ACR Convergence 2023
Two- and Three-Year Outcomes from the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study
Sarah Ringold¹, George Tomlinson², Laura Schanberg³, vincent del gaizo⁴, Katherine Murphy⁵, Brian Feldman⁶, Mei-Sing Ong⁷, Marc Natter⁸, Yukiko Kimura⁹ and For The CARRA Registry Investgators⁴, ¹Seattle Children's Hospital, Seattle, WA, ²University of Toronto, Toronto, ON, Canada, ³Duke University School of Medicine, Durham, NC, ⁴CARRA, Inc, Washington, DC, ⁵Non-clinical, New Orleans, LA, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, MA, ⁸Harvard Medical School, Boston, MA, ⁹Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: The STOP-JIA study was designed to compare the effectiveness of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Consensus Treatment Plans (CTPs) for untreated…
Abstract Number: 018 • 2023 Pediatric Rheumatology Symposium
Using the Electronic Health Record to Identify Subjects with Rheumatic Disease
Alysha Taxter¹, Matthew Basiaga², Rajdeep Pooni³, Caitlan Pinotti⁴, Lisa Buckley⁵ and CARRA Registry Investigators⁶, ¹Nationwide Children's Hospital, Columbus, OH, ²Mayo Clinic, Rochester, MN, ³Stanford University, Palo Alto, CA, ⁴Duke, Durham, NC, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶CARRA, Washington, DC
Background/Purpose: Research teams spend hours manually searching the electronic health records (EHRs) to identify potential candidates eligible for recruitment to the Childhood Arthritis and Rheumatology…
Abstract Number: 020 • 2023 Pediatric Rheumatology Symposium
Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model
Margaret Chang¹, Maryrose Hahn¹, Brian Wauford¹, Rachel Blaustein², Kevin Wei² and Peter Nigrovic¹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Most rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) patients experience episodic arthritis flares and require life-long medications to control their disease. We observed…
Abstract Number: 103 • 2023 Pediatric Rheumatology Symposium
Clinical, Serologic, and Imaging Findings of Rhupus Syndrome in the Pediatric Population: A Systematic Literature Review
Muriel Velez, Bryan Nicolalde, Kevin Moreno-Montenegro, Gabriela Carolina Carrera-Barriga, Camila Gallegos and Beatriz Leon, Universidad San Francisco de Quito, Quito, Ecuador
Background/Purpose: Pediatric Rhupus syndrome is a complex autoimmune disease characterized by overlapping clinical and immunological features of Juvenile Idiopathic Arthritis (JIA) and juvenile Systemic Lupus…
Abstract Number: 2207 • ACR Convergence 2022
Structural Ultrasound Features of Joints and Tendons of Healthy Children: Development of Normative Data
Ruth Wittoek¹, Céline Decock², Nele Dewaele², Lara Arnold³, Pieter baeyens⁴, Ignace Deschrijver⁴, Lisa Pardaens⁵, Ioannis Raftakis⁶, Thomas Renson⁷, Alexander D.J. Thooft⁸, Charline Rinkin⁹, Tine Vanhaverbeke⁵ and Caroline Verbist¹⁰, ¹Dept. of Rheumatology, Ghent University Hospital, Ghent University, Gent, Belgium, ²Ghent University, Faculty of Medicine, Ghent, Belgium, ³Dept. Of Rheumatology, Maastricht UMC+, Maastricht, Netherlands, ⁴Dept. of Radiology, Clinique de Flandre, Coudekerque-Branche, France, ⁵Ghent University, Faculty of Internal Medicine and Pediatrics, Gent, Belgium, ⁶Dept. of Rheumatology, CHU-Brugmann Hospital Brussels, Brussels, Belgium, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Ghent University, Faculty of Internal Medicine and Pediatrics, Ghent, Belgium, ⁹Dept. of Rheumatology, CHU Liège, Liège, Belgium, ¹⁰Dept. of Rheumatology, AZ Delta, Roeselare, Belgium, Roeselare, Belgium
Background/Purpose: Ultrasound is a highly valuable imaging modality to study joints in patients with rheumatic diseases. In children, the applicability is hampered because of lack…
Abstract Number: 2212 • ACR Convergence 2022
Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials
Hermine Brunner¹, Athimalaipet Ramanan², Gerd Horneff³, Kirsten Minden⁴, Inmaculada Calvo Penades⁵, Mauro Zucchetto⁶, Laura Brockwell⁷, Oliver Gordon⁷ and Fabrizio De Benedetti⁸, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ²Bristol Royal Hospital for Children, Bristol, United Kingdom, ³Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, ⁶Parexel International, Milano, Italy, ⁷Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁸Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy
Background/Purpose: Dosing regimens for subcutaneous tocilizumab (SC-TCZ) in patients with polyarticular-course or systemic juvenile idiopathic arthritis (pJIA or sJIA) were determined for SC-TCZ in 2…
Abstract Number: 0808 • ACR Convergence 2022
Transitional Care in Juvenile Idiopathic Arthritis: Timing, Prevalence of Subtypes and Treatment Profile in a Spanish Tertiary Hospital
Cristobal Pavez Perales¹, Alba Torrat Novés², José Ivorra Cortés¹, Samuel Leal Rodriguez¹, Anderson V Huaylla Quispe³, Carmen Riesco Bárcena², Laura Mas Sanchez¹, Pablo Muñoz Martinez⁴, Elena Grau García¹, Elvira Vicens Bernabeu¹, José Eloy Oller Rodrígez¹, Francisco Miguel Ortiz Sanjuan⁵, Isabel Martínez-Cordellat¹, Rosa Negueroles Albuixech¹, Berta Lopez Montecinos⁶, Carmen Nájera Herranz¹, Inés Cánovas Olmos¹, Daniel Ramos Castro¹, Inmaculada Calvo Penades⁷, Luis González Puig⁸ and José andrés Román ivorra⁹, ¹Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ³Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁴Rheumatology Department. Hospital Universitario y Politécnico La Fe, Sagunto, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, Spain, Spain, ⁶Pediatric Rheumatology Unit. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ⁷Pediatric Rheumatology Unit, Hospital Universitario y Politécnico La Fe, València, Spain, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain, ⁹Hospital Universitari i Politécnic la Fe, València, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the leading cause of chronic inflammatory rheumatic disease in children. It's classified into subtypes with different relative prevalences depending…
Abstract Number: 0867 • ACR Convergence 2022
Regulatory Haplotype of CXCR4 Is Associated with sJIA and Corelates with Enhanced Neutrophil and CD14+ Monocyte Migration
Hiroto Nakano¹, Emily Shuldiner², Anne Hinks³, Marc Sudman⁴, Elaine Remmers⁵, Colleen Satorius⁶, Elizabeth Schmitz¹, Victoria Arthur⁷, Patricia Woo⁸, Alexei Grom⁹, Dirk Foell¹⁰, John Bohnsack¹¹, Marco Gattorno¹², Seza Ozen¹³, Sampath Prahalad¹⁴, Rae Yeung¹⁵, Elizabeth Mellins², Sheila Oliveira¹⁶, Jordi Antón¹⁷, Claudio Len¹⁸, Carol Lake¹⁹, Ly-Lan Bergeron²⁰, Michelle Millwood²¹, Estefania de los santos²¹, Mariana Correia Marques²², Juvenile Arthritis Consortium for the Immunochip²³, The Genomic Ascertainment Cohort Investigators²⁴, INCHARGE Consortium²⁵, Carl Langefeld²⁶, Susan Thompson²⁷, Wendy Thomson²⁸ and Michael Ombrello¹, ¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ²Stanford University, Stanford, CA, ³The University of Manchester, Manchester, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵National Human Genome Research Institute, Bethesda, MD, ⁶NHGRI, NIH, Bethesda, MD, ⁷Boston Children's Hospital, Boston, MA, ⁸University College London, London, United Kingdom, ⁹Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰University Hospital Münster, Münster, Germany, ¹¹University of Utah, Salt Lake City, UT, ¹²Pediatric Clinic and Rheumatology Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹³Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹⁶Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil, ¹⁷Pediatric Rheumatology Department. Hospital Sant Joan de Déu. Universitat de Barcelona, Esplugues de Llobregat, Spain, ¹⁸Universidade Federal de São Paulo, São Paulo, Brazil, ¹⁹NIH, Gaithersburg, MD, ²⁰NIH/NIAMS, Vienna, VA, ²¹NIAMS, NIH, Bethesda, MD, ²²National Institute of Arthritis and Musculoskeletal and Skin Diseases / Children`s National Hospital, Bethesda, MD, ²³Juvenile Arthritis Consortium for the Immunochip, Bethesda, MD, ²⁴The Genomic Ascertainment Cohort Investigators, Bethesda, MD, ²⁵International Childhood Arthritis Genetics Consortium, Bethesda, MD, ²⁶Wake Forest School of Medicine, Winston Salem, NC, ²⁷Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ²⁸Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare inflammatory disease that causes spiking fever, skin rash, chronic arthritis, and inflammation of the heart and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].